Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, injecting platelet-rich plasma into the muscular layer of the intestinal wall in rabbits significantly reduced adhesion development compared to soaking methods, suggesting an improvement in anastomosis regeneration.

In this study, researchers developed a novel delivery system using hyaluronic acid gels to encapsulate Huperzine A for Alzheimer's treatment, achieving extended release over 20 days and significantly improving pathology and behavior in mice, including enhanced memory and reduced neuroinflammation.

In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.

This study identified common and unexpected adverse events associated with ritlecitinib in real-world use, providing insights into its safety profile for treating severe alopecia areata.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

This report describes two cases where patients developed vitiligo as a side effect of diphencyprone treatment for alopecia areata, highlighting the need to inform patients about this potential adverse effect.

In this study, injectable microdepots containing rapamycin and poly(lactic-co-glycolic acid) were developed and demonstrated to effectively promote hair regrowth in mice by sustaining drug release and inducing anagen phase transition in hair follicles through modulating autophagy and the Wnt/β-catenin pathway.

This case report describes a cat that developed alopecia and hyperactivity after ingesting valproic acid from contaminated household food, with symptoms resolving after the drug was removed.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

Raltegravir may cause hair loss in some patients.

This study found that diphencyprone is an effective and safe treatment for extensive alopecia areata, especially with long-term therapy and maintenance to reduce relapse risk.

This report discusses a case of localized hypertrichosis that developed after an elderly male with Alzheimer's disease started oral rivastigmine therapy, suggesting a potential link between the drug and hair growth.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

In this study, a specific retinoic acid receptor antagonist caused severe craniofacial anomalies in mouse fetuses when administered early in pregnancy, but not limb anomalies, highlighting developmental stage-specific roles of retinoic acid.

This case report highlights two instances of alopecia areata, demonstrating diverse presentations, and suggests upadacitinib as a promising treatment option, resulting in hair regrowth within 3–6 months, without worsening sarcoidosis-related skin lesions.

In this study, researchers at Nottingham Children's Renal Unit found that most pediatric patients switching from Prograf to the generic tacrolimus preparation Adoport maintained stable tacrolimus levels and therapeutic effectiveness, supporting Adoport's use as a cost-saving alternative for the NHS.

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

This report describes a case in which poststreptococcal reactive arthritis in a girl was effectively treated with naproxen, and highlights the importance of considering nongroup A Streptococcus in similar presentations.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This report describes a case where rituximab provided durable remission in a patient with refractory aggressive diffuse B-cell lymphoma that was unresponsive to prior chemotherapy.

Some people have severe allergic reactions to anthelminthic drugs, but these are often due to the parasites, not the drugs.

This review discusses recent advances in polydopamine-based biomaterials and their growing potential in personalized medicine, but reports no new experimental results; the authors highlight both opportunities and challenges for future applications.

In this study, researchers identified compound 30a as a promising topical androgen receptor antagonist that promoted hair growth in mouse models of androgenetic alopecia without noticeable toxicity, suggesting its potential for treating this hair loss condition.

This study found that two-thirds of patients with persistent chronic daily headache showed significant improvement with divalproex sodium treatment, although common side effects included weight gain, tremor, hair loss, and nausea.

This case report observed vemurafenib-induced pityriasis amiantacea, a scalp scaling reaction, in a patient with metastatic melanoma, which was managed symptomatically without altering vemurafenib treatment.

This case report describes a patient who developed severe alopecia and a rash after increasing captopril dosage, which resolved upon discontinuing the medication.

Tofacitinib might be used to treat hair loss.

This study reported the development of pH-responsive nanoparticles that effectively deliver vancomycin in a controlled manner, demonstrated enhanced antibacterial activity, and showed promise for clinical applications by targeting bacterial infection sites with programmable drug release.

In this study, researchers found that hair changes, particularly anagen effluvium, were the most common mucocutaneous side effects in cancer patients undergoing chemotherapy, occurring in 31.71% of cases, followed by skin, nail, and mucosal changes, highlighting the morbidity associated with antineoplastic drug side effects.

This study suggests that adding imiquimod to diphenylcyclopropenone treatment significantly improves outcomes for alopecia areata patients who initially do not respond to diphenylcyclopropenone alone.